Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Short Interest Update

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) was the target of a large growth in short interest in September. As of September 15th, there was short interest totaling 45,625 shares, a growth of 58.3% from the August 31st total of 28,830 shares. Currently, 1.5% of the company’s stock are sold short. Based on an average daily volume of 33,064 shares, the days-to-cover ratio is currently 1.4 days.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Weiss Ratings began coverage on shares of Eloxx Pharmaceuticals in a report on Friday, August 14th. They issued a “sell (d)” rating for the company. Lifesci Capital began coverage on Eloxx Pharmaceuticals in a report on Wednesday, July 22nd. They set an “outperform” rating and a $40.00 target price on the stock. Lucid Cap Mkts upgraded Eloxx Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 20th. Leerink Partners set a $32.00 price target on Eloxx Pharmaceuticals and gave the stock an “outperform” rating in a research note on Friday, September 18th. Finally, Guggenheim reissued a “buy” rating and set a $43.00 price objective on shares of Eloxx Pharmaceuticals in a report on Monday, August 24th. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $38.33.

Eloxx Pharmaceuticals Trading Down 0.7%

NASDAQ ELOX traded down $0.11 during trading on Wednesday, hitting $15.31. The company’s stock had a trading volume of 14,329 shares, compared to its average volume of 26,908. The firm has a market cap of $61.85 million, a price-to-earnings ratio of -9.94 and a beta of -1,862.26. Eloxx Pharmaceuticals has a 52 week low of $8.20 and a 52 week high of $23.40. The business’s 50 day moving average is $16.53.

Eloxx Pharmaceuticals (NASDAQ:ELOX) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc was a clinical-stage biopharmaceutical company focused on developing therapies for genetic diseases caused by nonsense mutations, which can prevent cells from producing functional proteins. The company’s research platform centered on ribosome modulation, an approach intended to encourage cells to read through certain premature stop signals in genetic instructions.

Its lead product candidate, ELX-02, was an investigational small-molecule therapy designed to promote the production of full-length proteins in diseases associated with nonsense mutations.